Patents by Inventor Robert McGuirk
Robert McGuirk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11873266Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: GrantFiled: July 26, 2021Date of Patent: January 16, 2024Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, George William Farr, Paul Robert McGuirk, Christopher H Hall, Walter F. Boron
-
Patent number: 11801254Abstract: Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof.Type: GrantFiled: November 16, 2020Date of Patent: October 31, 2023Assignee: Aeromics, Inc.Inventors: Marc F. Pelletier, Paul Robert McGuirk, George William Farr
-
Patent number: 11725018Abstract: Provided are crystals of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate, compositions comprising the same, and methods of making and using such crystals.Type: GrantFiled: August 27, 2021Date of Patent: August 15, 2023Assignee: Aeromics, Inc.Inventors: Paul Robert McGuirk, Robert Zamboni, Melanie Bevill, Stephan Parent
-
Publication number: 20220204536Abstract: Provided are crystals of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate, compositions comprising the same, and methods of making and using such crystals.Type: ApplicationFiled: August 27, 2021Publication date: June 30, 2022Applicant: AEROMICS, INC.Inventors: Paul Robert MCGUIRK, Robert ZAMBONI, Melanie BEVILL, Stephan PARENT
-
Publication number: 20220143048Abstract: Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.Type: ApplicationFiled: June 16, 2021Publication date: May 12, 2022Inventors: Marc F. Pelletier, Paul Robert McGuirk, George William Farr, Robert Zamboni, John Colucci, Helmi Zaghdane
-
Publication number: 20220081391Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: ApplicationFiled: July 26, 2021Publication date: March 17, 2022Inventors: Marc F. Pelletier, George William Farr, Paul Robert McGuirk, Christopher H. Hall, Walter F. Boron
-
Patent number: 11117909Abstract: Provided are crystals of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate, compositions comprising the same, and methods of making and using such crystals.Type: GrantFiled: May 12, 2017Date of Patent: September 14, 2021Assignee: AEROMICS, INC.Inventors: Paul Robert Mcguirk, Robert Zamboni, Melanie Bevill, Stephan Parent
-
Publication number: 20210275549Abstract: Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof.Type: ApplicationFiled: November 16, 2020Publication date: September 9, 2021Applicant: Aeromics, Inc.Inventors: Marc F. PELLETIER, Paul Robert MCGUIRK, George William FARR
-
Patent number: 11084778Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: GrantFiled: May 17, 2018Date of Patent: August 10, 2021Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, George William Farr, Paul Robert McGuirk, Christopher H. Hall, Walter F. Boron
-
Patent number: 11086902Abstract: Disclosed are methods and apparatuses to provide a redo repeater that allows for no data loss protection without the performance impact to the primary database even when a significant geographical distance separates the primary and standby databases. The Repeater is a lightweight entity that receives redo from the primary database with the purpose of redistributing that redo throughout the primary/standby system configuration. The Repeater able to extend no data loss protection and switchover functionality to terminal standby databases even though the primary database does not need to have a direct connection with those destinations.Type: GrantFiled: September 27, 2018Date of Patent: August 10, 2021Assignee: Oracle International CorporationInventors: Steven McGee, Jiangbin Luo, Benedicto Garin, Mahesh Girkar, Michael Harvey, Nitin Karkhanis, Steve Lee, Juan Loaiza, Robert McGuirk, Hongjie Yang
-
Patent number: 11071744Abstract: Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.Type: GrantFiled: October 28, 2019Date of Patent: July 27, 2021Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, Paul Robert McGuirk, George William Farr, Robert Zamboni, John Colucci, Helmi Zaghdane
-
Patent number: 10894055Abstract: Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof.Type: GrantFiled: December 31, 2018Date of Patent: January 19, 2021Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, Paul Robert McGuirk, George William Farr
-
Publication number: 20200297740Abstract: Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.Type: ApplicationFiled: October 28, 2019Publication date: September 24, 2020Applicant: AEROMICS, INC.Inventors: Marc F. PELLETIER, Paul Robert MCGUIRK, George William FARR, Robert ZAMBONI, John COLUCCI, Helmi ZAGHDANE
-
Publication number: 20190307779Abstract: Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof.Type: ApplicationFiled: December 31, 2018Publication date: October 10, 2019Applicant: Aeromics, Inc.Inventors: Marc F. PELLETIER, Paul Robert MCGUIRK, George William FARR
-
Publication number: 20190185496Abstract: Provided are crystals of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate, compositions comprising the same, and methods of making and using such crystals.Type: ApplicationFiled: May 12, 2017Publication date: June 20, 2019Applicant: AEROMICS, INC.Inventors: Paul Robert MCGUIRK, Robert ZAMBONI, Melanie BEVILL, Stephan PARENT
-
Patent number: 10258636Abstract: Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.Type: GrantFiled: October 24, 2017Date of Patent: April 16, 2019Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, Paul Robert McGuirk, George William Farr, Robert Zamboni, John Colucci, Helmi Zaghdane
-
Publication number: 20190026353Abstract: Disclosed are methods and apparatuses to provide a redo repeater that allows for no data loss protection without the performance impact to the primary database even when a significant geographical distance separates the primary and standby databases. The Repeater is a lightweight entity that receives redo from the primary database with the purpose of redistributing that redo throughout the primary/standby system configuration. The Repeater able to extend no data loss protection and switchover functionality to terminal standby databases even though the primary database does not need to have a direct connection with those destinations.Type: ApplicationFiled: September 27, 2018Publication date: January 24, 2019Applicant: Oracle International CorporationInventors: Steven McGee, Jiangbin Luo, Benedicto GARIN, Mahesh Girkar, Michael Harvey, Nitin Karkhanis, Steve Lee, Juan Loaiza, Robert McGuirk, Hongjie Yang
-
Publication number: 20180334424Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: ApplicationFiled: May 17, 2018Publication date: November 22, 2018Inventors: Marc F. PELLETIER, George William FARR, Paul Robert MCGUIRK, Christopher H. HALL, Walter F. BORON
-
Patent number: 10102266Abstract: Disclosed are methods and apparatuses to provide a redo repeater that allows for no data loss protection without the performance impact to the primary database even when a significant geographical distance separates the primary and standby databases. The Repeater is a lightweight entity that receives redo from the primary database with the purpose of redistributing that redo throughout the primary/standby system configuration. The Repeater able to extend no data loss protection and switchover functionality to terminal standby databases even though the primary database does not need to have a direct connection with those destinations.Type: GrantFiled: April 24, 2012Date of Patent: October 16, 2018Assignee: Oracle International CorporationInventors: Steven McGee, Jiangbin Luo, Benedicto Garin, Mahesh Girkar, Michael Harvey, Nitin Karkhanis, Steve Lee, Juan Loaiza, Robert McGuirk, Hongjie Yang
-
Publication number: 20180169118Abstract: Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.Type: ApplicationFiled: October 24, 2017Publication date: June 21, 2018Applicant: AEROMICS, INC.Inventors: Marc F. PELLETIER, Paul Robert MCGUIRK, George William FARR, Robert ZAMBONI, John COLUCCI, Helmi ZAGHDANE